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The process of consent 
 The process should be tailored to the type of study and 
circumstances of the populations being recruited: 
 How much time will the individual have to consider 
participation? 
 Where will the consent process occur?  The setting should be 
private. 
 Individuals involved in the consent process should have a 
good understanding of the study and be able to answer 
questions.   
 For treatment studies, we would expect there will be an overlap of 
clinical and research questions. 
 The overall consent process  (timing, setting and presentation 
of the study) should occur under circumstances that avoid 
coercion or undue influence. 
 
 
Who can obtain consent? 
 This should be described in your IRB application. 
 The IRB can require that certain individuals be 
involved in the consent process.   
 Example:  The IRB could determine that based on the 
risk and complexity of the study only the PI may obtain 
consent. 
 If the consent process is delegated by the PI to another 
individual they must be 
 fully trained  
 aware of all aspects of the study and; 
  the PI must  still be available to answer questions 
 
Residents obtaining consent 
 There are Institutional requirements for Human 
Subject Research Training 
 Satisfaction of this requirement is tracked in the 
myIRB application. 
 IRB must be aware of and approve all individuals 
“engaged” in the research to ensure qualifications and 
define IRB oversight. 
 Adding someone to the myIRB application-DEMO!! 
 The PI is responsible for ensuring that these 
individuals have a good understanding of the study 
and can answer questions. 
The Consent Document 
 The consent document is the only written record we 
have that says exactly what it is that you will tell the 
subject. 
 It must contain all information that a reasonable 
person needs to know to decide whether or not to 
participate in the study. 
 Should be presented in a way that is understandable. 
 It must contain information that addresses specific 
regulatory requirements. 
Signing the Consent Document 
 IRB policy: 
 Participant and person obtaining consent must sign and 
date the consent document 
 The participant (LAR, if applicable) must be provided 
with a signed copy of the consent document. 
Signing the Consent Document 
 Until the participant signs the consent document do not 
make assumptions based on earlier conversations 
 The participant could be in full agreement and the next 
day/hour/minute change their mind. 
 Once the participant signs, it will be the responsibility of the 
participant to let you know if they changed their mind. 
 Person obtaining consent 
 Not advisable to sign prior to the participant…why? 
 See prior bullet point 
 A “meeting of the minds”, “a mutual agreement” 
 Can create questions about the validity of the consent process. 
 Investigator acknowledgement 
 Not an IRB requirement 
Signing the Consent Document 
 The participant: 
 “Your signature indicates that this research study has 
been explained to you, that your questions have been 
answered, and that you agree to take part in this study.” 
 Person obtaining consent: 
 “The information in this document has been discussed 
with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The 
participant has indicated that he or she understands the 
risks, benefits, and procedures involved with 
participation in this research study.” 
 
Timing of Consent 
 The amount of time required by a subject to make a 
decision will depend on the nature of the study, the 
degree of risk, potential benefits, alternatives, and 
desire to consult with family members or others. 
 If a prolonged period of time elapses from the date of 
consent to the date of entry into the study even if there 
have been no changes in the study design or no new 
significant findings affecting the study it might be 
prudent to review the information contained in the 
consent form with the subject prior to initiating any 
research procedures with the subject. 
 OHRP FAQs on consent 
 
Decisionally impaired 
individuals 
 Enrolling individuals that are decisionally impaired or that could 
become decisionally impaired over time requires IRB approval. 
 Considered a vulnerable population 
 IRB will want to know: 
 Why is it ethically appropriate to include this population?   
 In the alternative, consider if it is appropriate to exclude the 
population. 
 How will you assess competency? 
 Will you obtain assent from the participant? 
 How will you consent the LAR? 
 How will you ensure the LAR understands their role? 
 
Use of the LAR 
 Who can sign? 
 If the participant has a legal guardian or attorney-in-fact 
this individual must sign as the LAR.    
 If there is no legal guardian or attorney-in-fact the individuals 
listed below may sign in order of priority.  
 (1) Spouse unless the participant has no spouse, or is separated, or 
the spouse is physically or mentally incapable of giving consent, or 
the spouse's whereabouts is unknown or the spouse is overseas; 
 (2) Adult child;  
 (3) Parent; 
 (4) Brother or sister;  
 (5) Relative by blood or marriage.  
 
 
Use of the LAR 
 How to use the priority list 
 Recognize that this process is different than in the 
clinical setting 
 There is no “reasonably available” exception when going 
down the priority list.   
 For example, if the participant does not have a spouse 
but has an adult child, that is the person that can 
provide consent.  You cannot go to the parent if they are 
more conveniently available. 
 
Use of LAR in minimal risk studies 
 Possible policy change forthcoming 
 For minimal risk studies where there is no legally 
appointed representative will allow other individuals 
listed on the priority list to give consent even if not 
first on the list. 
 
 
Non-English Speakers 
 Enrolling individuals that do not speak English 
requires prior IRB approval. 
 Whenever possible, the consent document should be 
in a language understandable to the subject, and 
include all the elements necessary for legally effective 
informed consent. Subjects who do not speak English 
should be presented with a consent document written 
in a language understandable to them.  Memo from OHRP 
 
Short Form 
 A “short form” includes an oral presentation of informed consent in 
conjunction with a short form document (stating that the elements of 
consent have been presented orally) and a written summary of what is 
presented orally. A witness to the oral presentation is required, and the 
subject must be given copies of the short form document and the 
summary. 
 Oral presentation and short form should be in language 
understandable to the subject 
 The English version of the consent may serve as the summary 
 The witness should be fluent in both English and the language of 
the subject 
 Short form signed by participant, the summary signed by person 
obtaining consent, the short form and summary signed by the 
witness (the translator may be the witness) 
 
Allowing use of the short form 
 When would the IRB allow use of the short form in lieu of a 
fully translated consent? 
 The issue:  Depending on the type of study the 
participant may need a reference document (the 
consent) or ongoing translational support to stay fully 
informed once they go home. 
 How complex is the study, what are the risks, what is the 
ongoing involvement of the participant? 
 
 
 
Other unique challenges 
 Physically unable to sign 
 Visual impairments 
 Unable to read or write 
 “Making their Mark” 
 
 We have guidance!! 
 
Physically unable to sign 
 The individual must be competent. 
 The individual must be able to indicate their approval 
or disapproval 
 Verbal, raise hand, nod 
 “making their mark” is considered a valid signature 
 Person obtaining consent should document the 
method used to communicate approval on the consent 
 Impartial witness present during consent process 
 Below signature block have witness sign and indicate 
they witnessed the consent process and the individual 
agreed to participant by <insert method>. 
Visual impairments/Cannot read or write 
 The individual must be competent. 
 The individual is able to indicate their approval or 
disapproval. 
 There must be continuing support to relay information in 
the consent document such as:  what is involved, risks, 
contact information for PI and WU IRB. 
 Procedure:   
 document method of agreement, if not signing consent or 
“making mark” 
 impartial witness present during consent process 
 written attestation to consent process by witness 
 
 
Take home points 
 The consent process is a critical element of good 
human subjects research and a critical part of the IRB 
review process. 
 The consent process will be driven by the 
circumstances of the study.  
 The signatures should represent the flow of the 
consent process. 
 When using LARs research is different than clinical 
care 
 Tell the IRB what you are doing!! 
 
Questions? 
 
